Shanghai INT Medical Instruments Co., Ltd.

About Shanghai INT Medical Instruments Co., Ltd.

Shanghai INT Medical Instruments Co., Ltd. (formerly Shanghai Kangdelai Medical Instruments Co., Ltd.) was established on June 7, 2006, and is headquartered in Jiading District, Shanghai. The company was listed on the Main Board of the Hong Kong Stock Exchange on July 10, 2019, under stock code 01501. It is a leading domestic manufacturer of interventional medical devices in China, specializing in R&D, production, and sales of Class III medical devices across cardiovascular, peripheral, neurovascular, orthopedic, and other medical fields. With over 1,700 employees and annual revenue of RMB 852 million by the end of 2024, INT Medical is recognized as a national high-tech enterprise and a “Little Giant” under the Specialized, Refined, Distinctive, and Innovative program.

Development History

In 2019, INT Medical completed its IPO on the Hong Kong Stock Exchange, raising HKD 832 million. In May 2025, the company, together with Shanghai Science and Technology Venture Investment Co., Ltd., acquired over 81% equity of Hangzhou Weiqiang Medical Technology Co., Ltd., securing more than 51% controlling interest. The company also officially changed its name from Shanghai Kangde莱 Medical Instruments Co., Ltd. to Shanghai INT Medical Instruments Co., Ltd.

Core Business & Product Pipeline

INT Medical’s business covers interventional devices in cardiovascular, peripheral vascular, neurovascular, and orthopedic fields. Its key products include balloon dilation pressure pumps, guiding catheter sheath sets, angiographic guidewires, controllable bend guiding catheters, and hemorrhoid ligation guidewires. In the cardiovascular field, the company is expanding into innovative technologies such as absorbable stents. Its flagship product lines include:

• Aortic stent system – including the WeFlow-Tbranch modular branch-type thoracic aortic stent and the Fabulous stent, targeting aortic dissection and aneurysms.

• Peripheral vascular interventional devices – products like VaSabre peripheral balloon dilation catheter and VSnare™ retrieval device for treating arteriosclerosis obliterans and deep vein thrombosis.

• Venous interventional devices – including the Grency® iliac vein stent developed by Weiqiang Medical, the first NMPA-approved iliac vein stent in china.

By 2024, the company owned 94 domestic registrations, 27 CE-certified products, 25 FDA-certified products, 406 authorized patents, and multiple software copyrights.

Market Position & Flagship Products

INT Medical’s products meet ISO13485, CE, and FDA standards and are exported to more than 80 countries and regions worldwide. The 2024 acquisition of Weiqiang Medical strengthened its portfolio in peripheral vascular devices and enabled entry into the high-end cardiovascular interventional field, breaking foreign dominance and driving domestic substitution in China’s interventional device sector.

Recent Developments

In 2025, INT Medical achieved multiple milestones: approval for its disposable invasive pressure sensor (August), disposable hydrophilic guidewire (September), and controllable bend guiding catheter (September) by the Shanghai Municipal Drug Administration. It was also listed as a “Specialized, Refined, Distinctive, and Innovative” enterprise under the Zhuanjing Teixin platform. In May 2025, the company announced the RMB 513 million acquisition of Hangzhou Weiqiang Medical Technology Co., Ltd.

Awards & Honors

The company has been recognized as a National Intellectual Property Advantage Enterprise, a Shanghai Municipal Enterprise Technology Center, a Patent Demonstration Enterprise, and a “Shanghai Innovative Enterprise Headquarter.”

Contact Information

• Shanghai Office: No. 925, Jin Yuan Road, Jiading District, Shanghai

• Hong Kong Headquarters: Times Square, 1勿地臣 Street, Causeway Bay, Hong Kong

• Phone: +86 21 6998 8888